Unique ID issued by UMIN | UMIN000043088 |
---|---|
Receipt number | R000049099 |
Scientific Title | Physician Awareness and Understanding of Primary Immunodeficiency Disorder: A Web-based Study |
Date of disclosure of the study information | 2021/01/22 |
Last modified on | 2024/07/05 09:55:43 |
Physician Awareness and Understanding of Primary Immunodeficiency Disorder:
A Web-based Study
PID-JAPAN physician survey study
Physician Awareness and Understanding of Primary Immunodeficiency Disorder:
A Web-based Study
PID-JAPAN physician survey study
Japan |
Primary Immunodeficiency Disorder
Medicine in general | Hematology and clinical oncology | Pediatrics |
Adult |
Others
NO
To determine the level of awareness of PID and understanding the diagnostic flow in PID in clinical practice
Others
To determine the level of awareness of PID and understanding the diagnostic flow in PID in clinical practice
Exploratory
Others
Not applicable
To determine the level of awareness of PID and understanding the diagnostic flow in PID in clinical practice
To determine the DDx between PID w/o IgG deficits including current treatment of PID
To determine the awareness and usefulness of TIPs(10 warning signs) to consider PID in clinical settings.
Observational
18 | years-old | <= |
Not applicable |
Male and Female
1)Physicians registered to Nikkei BP panel.
2)Physicians certified by medical societies as; General internal medicine and/or Pediatrics and/or Hematology.
1) Have less than 2 year of practice excluding training period
2) Work in a facility other than clinics, university hospitals, general hospitals and; national and public hospitals
3) Currently treating 0 outpatients and inpatients
350
1st name | 1)Yoich, 2)Kohsuke |
Middle name | |
Last name | 1) Inoue, 2) Imai |
1)Takeda Pharmaceutical Company Limited
2)National Defense Medical College
1)Japan Medical Office, 2)Department of Pediatrics
103-8668
1) 1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, Japan
070-4921-7478
yoichi.inoue@takeda.com
1st name | Akinori |
Middle name | |
Last name | Oh |
Takeda Pharmaceutical Company Limited
Japan Medical Office
103-8668
1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, Japan
080-2413-7663
akinori.oh@takeda.com
Takeda Pharmaceutical Company Limited
None
Self funding
Japan
None
Non-Profit Organization MINS Institutional Review Board
1-15-14 Dogenzaka, Shibuya-ku, Tokyo
03-6416-1868
npo-mins@j-irb.com
NO
NA
2021 | Year | 01 | Month | 22 | Day |
https://doi.org/10.1080/25785826.2022.2137966
Published
https://doi.org/10.1080/25785826.2022.2137966
355
45% physicians knew PID's symptoms and clinical conditions but 20% was aware of the diagnostic criteria and the recommended treatment. After presentation of patients' medical history, 74% physicians suspected PID and 60% physicians considered labo-tests for Serum IgG (IgA:55%, IgM:56%,IgE:33%). 72 physicians currently treated PID and 33% physicians who treated PID answered they control; serum immunoglobulin G trough level at 400-500 mg/dL, which is lower than the globally recommended standard value.
2022 | Year | 11 | Month | 07 | Day |
355 physicians (121 pediatricians, 116 hematologists and 118 general internal medicine physicians)
A web-based survey was conducted between 25 Jan 2021 and 12 Feb 2021 among Japanese physicians who were registered by Nikkei BP. The survey included 10 warning signs of PID and original questionnaires.
NA
NA
NA
NA
Main results already published
2020 | Year | 11 | Month | 05 | Day |
2021 | Year | 01 | Month | 21 | Day |
2021 | Year | 01 | Month | 22 | Day |
2021 | Year | 03 | Month | 31 | Day |
Physician Awareness and Understanding of Primary Immunodeficiency Disorder:
A Web-based Study
2021 | Year | 01 | Month | 22 | Day |
2024 | Year | 07 | Month | 05 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049099